Wegovy and Ozempic contain the exact same active ingredient, semaglutide, made by the same manufacturer. The difference is what they’re approved for and how much you take. Wegovy is FDA-approved for weight management and cardiovascular risk reduction, while Ozempic is approved for type 2 diabetes. Which one is “better” depends entirely on why you need it.
Same Drug, Different Purpose
Semaglutide works by mimicking a gut hormone called GLP-1, which slows digestion, reduces appetite, and helps regulate blood sugar. Both medications deliver it as a once-weekly injection. But the FDA treats them as separate products with distinct approved uses.
Ozempic is approved specifically for improving blood sugar control in adults with type 2 diabetes. In clinical trials, patients starting with an average A1c of 8.3% saw it drop by 1.5 percentage points, a significant improvement that outperformed other diabetes medications in the same class.
Wegovy carries broader approvals. It’s indicated for long-term weight management in adults with obesity (BMI of 30 or higher) or overweight (BMI of 27 or higher) with at least one weight-related condition. In March 2024, the FDA also approved Wegovy to reduce the risk of heart attack, stroke, and cardiovascular death in adults with heart disease who also have obesity or overweight. That cardiovascular approval is unique to Wegovy and does not apply to Ozempic.
The Dose Makes the Difference
Because they target different conditions, Wegovy and Ozempic top out at different doses. Both start at 0.25 mg per week and gradually increase, but they diverge after the first couple of months.
- Ozempic has a typical maintenance dose of 1 mg per week, with a maximum of 2 mg. The goal is blood sugar control, which can often be achieved at lower doses.
- Wegovy ramps up to a maintenance dose of 1.7 mg or 2.4 mg per week. The higher ceiling reflects the higher doses needed for meaningful weight loss and cardiovascular benefit.
This is the main reason Wegovy tends to produce more weight loss than Ozempic when compared head to head. It’s not a different drug. It’s more of the same drug.
Heart Health Benefits
The SELECT trial, a large cardiovascular outcomes study, found that semaglutide at Wegovy’s dose reduced major cardiovascular events by roughly 28% in patients with obesity or overweight and existing heart disease. Among patients with heart failure specifically, the benefit was even more pronounced, with reductions of 31% to 35% depending on the type of heart failure.
This is a meaningful distinction. If you have both a weight problem and cardiovascular risk, Wegovy is the only semaglutide product with FDA backing for that specific combination. Ozempic has not been studied or approved for this purpose.
Insurance Coverage and Cost
This is where the choice between Wegovy and Ozempic often gets made for you. Insurance coverage differs dramatically based on the indication.
Ozempic, as a diabetes medication, is covered by most insurance plans including Medicaid, which is required to cover FDA-approved diabetes drugs. Wegovy’s coverage is far less predictable. Weight loss drugs fall into a category that insurers, including Medicaid, can choose to exclude. As of January 2026, only 13 state Medicaid programs cover GLP-1 medications for obesity treatment. Even when covered, these drugs typically require prior authorization, adding another hurdle.
Wegovy’s newer cardiovascular approval has opened a separate coverage pathway. Since March 2024, Medicaid programs are required to cover Wegovy when prescribed for cardiovascular risk reduction. This matters if your doctor can document heart disease alongside obesity or overweight, because it may qualify you for coverage that a weight-loss-only prescription would not.
Without insurance, both drugs carry list prices above $1,000 per month. The semaglutide shortage that began in 2022 due to surging demand has been officially resolved as of February 2025, so availability is no longer the barrier it once was.
Pen Design and Practical Use
There’s a small but practical difference in how the two are packaged. Ozempic comes as a multi-use pen, meaning one pen contains several doses and you dial up the correct amount each week. Wegovy uses single-use prefilled pens, one pen per injection. The single-use design is simpler since there’s no dose dialing, but it also means more pens to store and dispose of. Both are injected under the skin in the stomach, thigh, or upper arm.
Which One Should You Ask About
If you have type 2 diabetes, Ozempic is the straightforward choice. It’s approved for your condition, your insurance is far more likely to cover it, and the doses used for blood sugar control are effective for most people. You’ll likely lose some weight as a secondary benefit, though less than you would on Wegovy’s higher dose.
If your primary goal is weight loss and you don’t have diabetes, Wegovy is the appropriate option. Its higher maintenance dose is specifically calibrated for weight management, and it’s the only version with clinical trial data supporting long-term use for that purpose. The challenge is getting it covered.
If you have cardiovascular disease along with obesity or overweight, Wegovy stands apart. It’s the only semaglutide product approved to reduce heart attack, stroke, and cardiovascular death in that population, and this indication may improve your chances of insurance coverage compared to a weight-loss-only prescription.
Side effects are essentially identical for both, since the active ingredient is the same. Nausea, vomiting, diarrhea, and constipation are most common, particularly during the dose escalation phase, and tend to improve over time. The gradual dose increases in both products are designed to minimize these effects.